NCT06376851Active, not recruiting
AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management
DECIDE Registry: AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 20000 (estimated)
- First submitted
- 28 Mar 2024
- Start date
- 27 Mar 2024
- Primary completion date
- 27 Mar 2026
- Lead sponsor
- HeartFlow, Inc.
- Diseases
- Coronary artery disease
- NCT number
- NCT06376851
What you commit to
- Study type: Observational
- Planned participants: 20000
- From 27 Mar 2024 to the primary completion date, 27 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Groups 1,2,3,4, and 6: Previous history of CAD (prior to the CCTA or stress test with history of revascularization)
- Group 5: Prior history of PCI in multiple vessel territories, PCI in the Left Main, CABG, and/or any other conditions or limitations which would prevent successful CCTA processing by HeartFlow
- Previously evaluated with and/or in a study which includes AI-QCPA
Other
- ED presentation (at the time of the CCTA or stress test)
- Acute chest pain (in patients who have not been ruled out for ACS)
Who the study is looking for
- Groups 1, 2,4,5 and 6: CCTA and plaque detected
- Group 3: Any patient with a stress test (stress echocardiogram or nuclear imaging including SPECT or PET) and no CCTA within the 90 days prior to site activation
- Groups 1,2,3 and 4: Clinically stable, symptomatic
- Group 6: Clinically stable without symptoms suggestive of CAD at the time of the CCTA
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moses Cone Memorial Hospital Coordinator of this site? Confirm its status | Greensboro | United States | Unknown status |
Related publications
- Guiding Preventive Care Strategies for Patients With Atherosclerotic Plaque on Coronary CTA: Primary Outcomes of the DECIDE Registry.JACC Cardiovasc Imaging · 2026 · PMID 41817483
This page is information, not medical advice. Discuss any trial with your doctor.